University of California, San Diego

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, San Diego sits in the top decile of US sponsors by registered trial count (#43 of 15,742 sponsors by registered trial count).

775 total trials 143 currently recruiting 499 completed early-phase tilt top decile by trial count

University of California, San Diego: 775 sponsored US clinical trials, 143 recruiting.

University of California, San Diego sponsors 775 registered US clinical trials on ClinicalTrials.gov, 143 of them currently recruiting, and 499 completed. 104 of these trials are in Phase 3-4 (later-stage) and 170 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Anorexia Nervosa, with 10 trials.

Top-decile sponsor footprint

University of California, San Diego ranks in the top decile of sponsors by registered trial count (#43 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 65/100

499 of 553 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

775 total, page 15 of 16

COMPLETED Phase 4

Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder

NCT00662259

COMPLETED NA

PACE-PC: Primary Care Management of Adolescent Obesity

NCT00415974

COMPLETED Phase 4

PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)

NCT00703885

COMPLETED NA

Imaging Outcomes of Cognitive Behavioral Therapy (CBT) for Battered Women With Posttraumatic Stress Disorder

NCT01517672

COMPLETED NA

Physical Activity and Basal Metabolic Rate in Postmenopausal Women

NCT01550536

COMPLETED NA

Paracervical Versus Intracervical Lidocaine

NCT00816751

TERMINATED NA

Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction

NCT00574756

COMPLETED

Study of Surgically-Induced Weight Loss on Pelvic Floor Disorders

NCT00884871

COMPLETED NA

Single Incision Laparoscopy

NCT00616616

COMPLETED

Minimally Invasive Surgery (MIS) Database for the Purpose of Research

NCT00535990

COMPLETED Phase 3

Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)

NCT00747617

COMPLETED

Minimally Invasive Surgery: Using Natural Orfices

NCT00530998

COMPLETED Phase 4

Ultrasound Guidance Versus Electrical Stimulation for Perineural Catheter Insertion

NCT00877266

COMPLETED Phase 2

Alcohol Use Disorders (AUDs) and Post-traumatic Stress Disorder (PTSD) Treatment for Victims of Partner Violence

NCT00607412

COMPLETED

Evaluating the Occurence of New and Progression of Existing Peripheral Venous Disease in Leg Veins

NCT00508079

COMPLETED NA

Cognitive Benefits of Treating Sleep Apnea in Parkinson's Disease

NCT00492115

COMPLETED NA

mDiet - Ecological Momentary Intervention of Diet Via Mobile Technology

NCT00415870

COMPLETED NA

Impact of a Mailed Educational Reminder on Fecal Occult Blood Testing (FOBT): A Randomized Controlled Trial

NCT00534053

TERMINATED

Characteristics of Dendritic Cells Before and After Gastric Banding

NCT00488930

COMPLETED NA

Breast Cancer Trials Education Program

NCT02808598

COMPLETED NA

Effect of Ambulatory Continuous Femoral Nerve Blocks on Readiness-for-Discharge Following Total Knee Replacement

NCT00419276

COMPLETED Phase 2

Clinical Trial of CNS-targeted HAART (CIT2)

NCT00624195

COMPLETED Phase 2

Behavior Change and Maintenance Intervention for HIV+ MSM Methamphetamine Users

NCT00432926

COMPLETED Phase 4

Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes

NCT00397020

TERMINATED Phase 4

How do Sleeping Pills Affect Pain in the Brain?

NCT00414037

COMPLETED Phase 1

A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia

NCT00614679

COMPLETED NA

STD Risk Reduction for Heterosexual Methamphetamine Users

NCT00344214

COMPLETED Phase 2

Seamos Activas: Increasing Physical Activity Among Latinas

NCT00724165

COMPLETED Phase 4

Effect of Eszopiclone on Sleep Disturbance and Pain in Cancer

NCT00365261

COMPLETED NA

Dietary Supplements for the Treatment of Angelman Syndrome

NCT00348933

COMPLETED NA

Trial of Quetiapine in Anorexia Nervosa

NCT00518973

COMPLETED NA

Effect of Exercise and Diet on Inflammation in Hypertensive Individuals

NCT00338572

COMPLETED NA

Enhancing Consent for Alzheimer's Research

NCT00453544

COMPLETED NA

PACEPro - Mood Management Pilot

NCT00416221

COMPLETED NA

Effects of Light Treatment During Sleep on Young Men

NCT00796939

COMPLETED Phase 4

A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules

NCT00281606

COMPLETED Phase 1

Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT00850057

COMPLETED NA

PACE-iDP: An Intervention for Youth at Risk for Diabetes

NCT00412165

COMPLETED Phase 1

Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma

NCT00398450

COMPLETED Phase 1

Effects of Lidocaine Patch on Intradermal Capsaicin Induced Pain and Hyperalgesia

NCT00373893

COMPLETED NA

Using Ultrasonography to Predict Clinical Response to Intraarticular Corticosteroids in Knee Osteoarthritis

NCT00414427

COMPLETED NA

Effect of Increased Light Exposure on Fatigue in Breast Cancer

NCT00478257

COMPLETED

Evaluating the Relationship Between Stress, Ethnicity, and Blood Pressure

NCT00783497

COMPLETED Phase 2

Effects of Hands-on-Healing vs. Touch for Fatigued Breast Cancer Survivors

NCT00440089

COMPLETED Phase 1

Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

NCT00766116

COMPLETED NA

Non-invasive Measurement of Microvascular Blood Flow During Mild External Compression of the Leg

NCT01804478

COMPLETED

Evaluating the Brain's Response to Natural Versus Artificial Sweetener in Women Who Have Had an Eating Disorder

NCT00517335

TERMINATED NA

Visualization of Cerebral Arteries Using Contrast-Enhanced Transcranial Ultrasound in Stroke Patients

NCT00282841

COMPLETED NA

Research in Autism: Parent Intervention

NCT01258465

COMPLETED NA

Weight Reduction Intervention for Breast Cancer Survivors

NCT00774371

← Previous Page 15 of 16 Next →

Phase Distribution

PhaseTrial count
Phase 1 80
Phase 2 90
Phase 3 22
Phase 4 82

What is open in the University of California, San Diego pipeline

143 recruiting of 775 indexed (18% open); 499 completed (64%).

Phase mix: 104 late (III/IV) vs 170 early (I/II) (early-phase heavy).

Top condition: Anorexia Nervosa (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, San Diego: open-pipeline peers nationwide

Peers matched on 775 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

University of California, San Diego sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 14%16%18%20%22% Total trials Recruiting share University of California, San DiegoDana-Farber Cancer InstituteMedical University of South CarolinaUniversity of ChicagoUniversity of UtahNeurocrine BiosciencesThomas Jefferson UniversityAbramson Cancer Center at Penn MedicineUniversity of Maryland, Baltimore
University of California, San Diego sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, San Diego sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 775 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this University of California, San Diego page

775 registered trials is a research-attention snapshot, not an endorsement of University of California, San Diego or any single study.

  • 143 of University of California, San Diego's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Anorexia Nervosa is the condition University of California, San Diego studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Anorexia Nervosa trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Diego pipeline card: 775 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.